In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models

BACKGROUND: Dendritic cells (DCs) are a promising therapeutic target in cancer immunotherapy given their ability to prime antigen-specific T cells, and initiate antitumor immune response. A major obstacle for DC-based immunotherapy is the difficulty to obtain a sufficient number of functional DCs. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Oba, Takaaki, Makino, Kenichi, Kajihara, Ryutaro, Yokoi, Toshihiro, Araki, Ryoko, Abe, Masumi, Minderman, Hans, Chang, Alfred E, Odunsi, Kunle, Ito, Fumito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166607/
https://www.ncbi.nlm.nih.gov/pubmed/34049930
http://dx.doi.org/10.1136/jitc-2021-002432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166607/
https://www.ncbi.nlm.nih.gov/pubmed/34049930
http://dx.doi.org/10.1136/jitc-2021-002432

Ejemplares similares